C07K 16/30
From tumour cells
Official title: from tumour cells
C07K16/30 (From tumour cells) appears on 7,312 US grants and 12,415 published applications in this corpus.
Search patents in C07K- Granted patents
- 7,312
- Published applications
- 12,415
- Assignees
- 3,009
- Inventors
- 16,026
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 3 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 6 | 0 |
| 1983 | 3 | 0 |
| 1984 | 8 | 0 |
| 1985 | 5 | 0 |
| 1986 | 11 | 0 |
| 1987 | 29 | 0 |
| 1988 | 26 | 0 |
| 1989 | 48 | 0 |
| 1990 | 46 | 0 |
| 1991 | 32 | 0 |
| 1992 | 39 | 0 |
| 1993 | 42 | 0 |
| 1994 | 33 | 0 |
| 1995 | 29 | 0 |
| 1996 | 60 | 0 |
| 1997 | 99 | 0 |
| 1998 | 102 | 0 |
| 1999 | 94 | 0 |
| 2000 | 79 | 0 |
| 2001 | 78 | 22 |
| 2002 | 80 | 144 |
| 2003 | 51 | 378 |
| 2004 | 55 | 225 |
| 2005 | 58 | 295 |
| 2006 | 90 | 277 |
| 2007 | 143 | 300 |
| 2008 | 157 | 304 |
| 2009 | 149 | 371 |
| 2010 | 199 | 357 |
| 2011 | 199 | 361 |
| 2012 | 213 | 325 |
| 2013 | 240 | 400 |
| 2014 | 280 | 479 |
| 2015 | 304 | 496 |
| 2016 | 357 | 681 |
| 2017 | 368 | 773 |
| 2018 | 386 | 732 |
| 2019 | 459 | 733 |
| 2020 | 465 | 749 |
| 2021 | 407 | 736 |
| 2022 | 395 | 719 |
| 2023 | 392 | 680 |
| 2024 | 405 | 788 |
| 2025 | 363 | 629 |
| 2026 | 223 | 461 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C07K 16/3069Reproductive system1,007
- C07K 16/3076Against structure-related tumour-associated moieties772
- C07K 16/3061Blood cells733
- C07K 16/3046Stomach, intestines682
- C07K 16/3015Breast674
- C07K 16/3023Lung569
- C07K 16/3053Skin, nerves, brain538
- C07K 16/303Liver or pancreas519
All 10 subgroupsShow fewer
Recent patents
- Mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy6 Oct 2026US 12,753,220 B2Cellectis
- Anti-ABCG2 antibodies and uses thereof6 Oct 2026US 12,753,241 B2William Robert Arathoon Living Trust Dated August 29, 2016
- CD5 chimeric antigen receptor for adoptive T cell therapy29 Sep 2026US 12,746,273 B2Baylor College of Medicine
- FOXM1-derived peptide, and vaccine including same29 Sep 2026US 12,747,265 B2Oncotherapy Science, Inc.
- Chimeric antigen receptor for treatment of cancer29 Sep 2026US 12,747,278 B2Industry-Academic Cooperation Foundation, Yonsei University
- Targeted Immune Cell Therapy Utilizing TRAIL and TNF Mediated Apoptosis8 Oct 2026US 2026/0306542 A1Northeastern University
- Anti-trop2 antibody-drug conjugates comprising pnu-159682 derivatives8 Oct 2026US 2026/0306652 A1Merck Sharp & Dohme Corp.
- Pharmaceutical composition for treatment of cancer, comprising an immune checkpoint inhibitor antibody and a fusion protein comprising an il-2 mutant and a cd80 extracellular domain8 Oct 2026US 2026/0308251 A1Gi Innovation, Inc.
- Anti-psma antibodies and uses thereof8 Oct 2026US 2026/0308273 A1Bristol-Myers Squibb Company
- Modified antibodies, antibody fragments thereof, and antibody-drug conjugates1 Oct 2026US 2026/0295063 A1Innovent Biologics (Suzhou) Co., Ltd.
Most cited
By later US patents
- Recombinant immunoglobin preparations4,785US 4,816,567 AGenentech, Inc. · 1989
- Single polypeptide chain binding molecules2,454US 4,946,778 AGenex Corporation · 1990
- Ransgenic non-human animals for producing heterologous antibodies1,941US 5,545,806 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,748US 5,569,825 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies1,680US 5,633,425 AGenPharm International, Inc. · 1997